Artificial intelligence is driving significant advances in immunotherapy and protein engineering. The Cold Spring Harbor Laboratory team introduced BATMAN, an AI model predicting T cell receptor (TCR) peptide binding with increased accuracy, aiding safer TCR therapy development. Separately, Nobel laureate David Baker’s group has harnessed AI to design specific, low immunogenicity protein binders targeting diverse disease markers, demonstrating rapid therapeutic protein creation capabilities. Additional AI-designed proteins have shown ability to enhance T cell cancer cell killing, marking new frontiers in scalable precision immunotherapies.